Inicio › Cáncer de próstata › Washington › Seattle
Ensayos clínicos de Cáncer de próstata en Seattle, WA
45 estudios para Cáncer de próstata buscan participantes en centros de Seattle y alrededores (a unos 30 millas). Abra un estudio para ver quién puede participar y cómo contactar con el equipo.
Texto oficial del estudio (inglés)
Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
ReclutandoFase 3
- Swedish Medical Center-Ballard Campus, Seattle
- Fred Hutchinson Cancer Center, Seattle
- Swedish Medical Center-Cherry Hill, Seattle
- y 4 más
Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer
ReclutandoFase 1
- Fred Hutchinson Cancer Center, Seattle
Study of Oral MRT-2359 With Apalutamide in Prostate Cancer
ReclutandoFase 2
- University of Washington Medical Center, Seattle
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
ReclutandoEstudio observacionalSe aceptan voluntarios sanos
- Swedish Medical Center-Ballard Campus, Seattle
- Swedish Medical Center-Cherry Hill, Seattle
- Swedish Medical Center-First Hill, Seattle
- y 1 más
Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial
ReclutandoFase 2
- Swedish Medical Center-First Hill, Seattle
A Study of JNJ-87189401 Combined With JNJ-78278343 for Advanced Prostate Cancer
ReclutandoFase 1
- Swedish Medical Center, Seattle
Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial
ReclutandoFase 3
- Swedish Medical Center-First Hill, Seattle
A Study of JNJ-78278343 in Combination With JNJ-95298177 for Treatment of Prostate Cancer
ReclutandoFase 1
- Fred Hutchinson Cancer Center, Seattle
Estrogen to Improve Quality of Life for Men With Newly Diagnosed or Recurrent Metastatic Hormone Sensitive Prostate Cancer, EQUIP Trial
ReclutandoFase 2
- Fred Hutch/University of Washington Cancer Consortium, Seattle
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
ReclutandoFase 3
- VA Puget Sound Health Care System ( Site 0054), Seattle
- Fred Hutchinson Cancer Center ( Site 0060), Seattle
Safety, Pharmacokinetics, and Preliminary Efficacy of VIR-5500 (AMX-500) in Prostate Cancer
ReclutandoFase 1
- Fred Hutchinson Cancer Research Center, Seattle
A Single-Arm Phase II Study of Neoadjuvant Intensified Androgen Deprivation (Leuprolide and Abiraterone Acetate) in Combination With AKT Inhibition (Capivasertib) for High-Risk Localized Prostate Cancer With PTEN Loss
ReclutandoFase 2
- VA Puget Sound Health Care System Seattle Division, Seattle, WA, Seattle
Precision-Based Genomics in Prostate Cancer
ReclutandoEstudio observacional
- University of Washington, Seattle
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
ReclutandoFase 3
- Virginia Mason Medical Center, Seattle
- Fred Hutchinson Cancer Center, Seattle
- FHCC at Northwest Hospital, Seattle
- y 1 más
Impact of DNA Repair Pathway Alterations on Sensitivity to Radium-223 in Bone Metastatic Castration-resistant Prostate Cancer
ReclutandoEstudio observacional
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Measuring Circulating Tumor Deoxyribonucleic Acid Tumor Fraction to Guide Early 177Lu-PSMA-617 Treatment Discontinuation in Patients With Metastatic Castration-Resistant Prostate Cancer, DYNAMO Trial
ReclutandoFase 2
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC
ReclutandoFase 3
- Swedish Medical Center, Seattle
Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
ReclutandoFase 3
- FHCC South Lake Union, Seattle
- FHCC at Northwest Hospital, Seattle
- University of Washington Medical Center - Montlake, Seattle
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
ReclutandoFase 1/2
- University of Washington, Fred Hutchinson Cancer Center, Seattle
Phase 1 Study of ACE-232 to Treat Patients With Metastatic Castration-Resistant Prostate Cancer
ReclutandoFase 1
- Fred Hutchinson Cancer Research Center, Seattle
Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy
ReclutandoFase 2/3
- Fred Hutchinson Cancer Research Center, Seattle
High Dose Testosterone for ATM, CDK12 or CHEK2 Altered Prostate Cancers
ReclutandoFase 2
- VA Puget Sound Health Care System Seattle Division, Seattle, WA, Seattle
Carboplatin or Olaparib for BRcA Deficient Prostate Cancer
ReclutandoFase 2
- VA Puget Sound Health Care System Seattle Division, Seattle, WA, Seattle
PROMISE Registry: A Prostate Cancer Registry of Outcomes and Germline Mutations for Improved Survival and Treatment Effectiveness
ReclutandoEstudio observacional
- University of Washington Medical Center, Seattle
The SUGAR Study; SBRT and Relugolix) for Prostate Cancer
ReclutandoFase 2
- University of Washington, Seattle
Prostate Active Surveillance Study
ReclutandoEstudio observacional
- Veterans Affairs Puget Sound Health Care System, Seattle
- University of Washington, Seattle
A Study of Talazoparib With or Without Enzalutamide in People With Prostate Cancer Who Have Previously Received Abiraterone Acetate or Darolutamide
ReclutandoFase 2
- Fred Hutchinson Cancer Center, Seattle
A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
ReclutandoFase 2
- Fred Hutchinson Cancer Center, Seattle
- University of Washington Medical Center, Seattle
Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate Cancer
ReclutandoFase 2
- Fred Hutchinson Cancer Center, Seattle
Cell Therapy (STEAP1 CART) With Enzalutamide for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer
ReclutandoFase 1/2
- Fred Hutch/University of Washington Cancer Consortium, Seattle
A Study to Assess BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer
ReclutandoFase 1
- Fred Hutchinson Cancer Center, Seattle
Vorinostat and 177Lu-PSMA-617 for the Treatment of PSMA-Low Metastatic Castration-Resistant Prostate Cancer
ReclutandoFase 2
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Collecting and Studying Blood and Tissue Samples From Patients With Locally Recurrent or Metastatic Prostate or Bladder/Urothelial Cancer
ReclutandoEstudio observacionalSe aceptan voluntarios sanos
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Evaluation of Neoadjuvant Xaluritamig in Localized Prostate Cancer
ReclutandoFase 1
- Fred Hutchinson Cancer Center, Seattle
Supraphysiological Androgen to Enhance Treatment Activity in Metastatic Castration-Resistant Prostate Cancer, SPECTRA Study
ReclutandoFase 2
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Exercise for Tumor Suppressive Impact in Men With Prostate Cancer at High-Risk of Progression on Active Surveillance: The REMOVE Trial
Reclutando
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
ReclutandoFase 3
- Swedish Medical Center-Ballard Campus, Seattle
- Fred Hutchinson Cancer Center, Seattle
- Swedish Medical Center-Cherry Hill, Seattle
- y 4 más
Study of ORIC-944 in Patients With Metastatic Prostate Cancer
ReclutandoFase 1
- University of Washington, Fred Hutchinson Cancer Center, Seattle
Low PSMA SUV Boost (LPS-Boost): Intensified 177Lu-PSMA-617 Treatment for Patients With Metastatic Castrate-Resistant Prostate Cancer With Low PSMA Expressing Disease
ReclutandoFase 2
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Abiraterone, Enzalutamide, or Apalutamide in Castrate-sensitive Prostate Cancer.
ReclutandoFase 2
- VA Puget Sound Health Care System, Seattle
Prostate Cancer Screening for People at Genetic Risk for Aggressive Disease, PATROL Study
ReclutandoEstudio observacionalSe aceptan voluntarios sanos
- Fred Hutch/University of Washington Cancer Consortium, Seattle
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
ReclutandoFase 1/2
- Fred Hutchinson Cancer Center, Seattle
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
ReclutandoFase 1
- Fred Hutchinson Cancer Center, Seattle
Carboplatin Chemotherapy Before Surgery for People With High-Risk Prostate Cancer and an Inherited BRCA1 or BRCA2 Gene Mutation
ReclutandoFase 2
- Swedish Medical Center-Ballard Campus, Seattle
- FHCC South Lake Union, Seattle
- Fred Hutchinson Cancer Research Center, Seattle
- y 4 más
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
ReclutandoEstudio observacional
- Massive Bio SYNERGY-AI site, Seattle
Más información sobre Cáncer de próstata en MedlinePlus
Ensayos de Cáncer de próstata en otras ciudades
- New York City, NY101 estudios
- Houston, TX73 estudios
- Los Angeles, CA64 estudios
- Boston, MA56 estudios
- St. Louis, MO45 estudios
- Chicago, IL45 estudios
- Baltimore, MD45 estudios
- San Francisco, CA44 estudios
- Philadelphia, PA41 estudios
- Nashville, TN40 estudios
- Washington, DC39 estudios
- Dallas, TX39 estudios
Otros estudios en Seattle
- Cáncer de pulmón de células no pequeñas55 estudios
- Cáncer (todos los tipos)48 estudios
- Leucemia mielógena aguda40 estudios
- Cáncer metastásico39 estudios
- Cáncer de seno37 estudios
- Cáncer del colon y del recto35 estudios
- Cáncer de pulmón34 estudios
- Cáncer de ovario29 estudios
- Cáncer de páncreas22 estudios
- Mieloma múltiple22 estudios
- Leucemia linfoblástica aguda22 estudios
- Leucemia linfocítica crónica22 estudios
De ClinicalTrials.gov, datos obtenidos el 15 nov 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.